Expression of p27/Kip1 is down-regulated in human prostate carcinoma progression

PL Fernandez; Y Arce; M. Farre; A Martinez; A Nadal; MJ Rey; N Peiro; E Campo; A Cardesa

doi:10.1002/(SICI)1096-9896(199904)187:5<563::AID-PATH292>3.0.CO;2-3

Expression of p27/Kip1 is down-regulated in human prostate carcinoma progression

PL Fernandez^*, Y Arce, M. Farre, A Martinez, A Nadal, MJ Rey, N Peiro, E Campo, A Cardesa

^*Corresponding author for this work

Research output: Contribution to journal › Article › Research › peer-review

47 Citations (Scopus)

Abstract

p27(Kip1) is a cyclin-dependent kinase inhibitor whose down-regulation has been observed in several tumour models, including breast, colorectal, and gastric carcinomas. The purpose of this study was to assess p27(Kip1) protein expression in normal and benign prostatic epithelia as well as the possible existence of abnormalities in prostate carcinoma progression. p27(Kip1) expression was immunohistochemically analysed in 51 normal tissue samples, 11 nodular hyperplasias (NH), 22 high-grade prostatic intraepithelial neoplasias (PIN), 56 localized prostate adenocarcinomas, and 19 metastases. Immunoblotting was performed in ten cases. Normal prostate epithelium and NH showed diffuse and intense p27(Kip1) nuclear expression in most cases. A significant p27(Kip1) down-regulation was observed in many carcinomas when compared with benign epithelium, Forty-seven cases (84 per cent) mere low p27(Kip1) expressors (

Original language	English
Pages (from-to)	563-566
Number of pages	4
Journal	J. Pathol.
Volume	187
Issue number	5
DOIs	https://doi.org/10.1002/(SICI)1096-9896(199904)187:5<563::AID-PATH292>3.0.CO;2-3
Publication status	Published - Apr 1999

Keywords

prostate cancer
prostate intraepithelial neoplasia
anti-oncogene
PIN
p27
Kip1
KINASE INHIBITOR P27(KIP1)
CELL-CYCLE
BREAST-CANCER
MOLECULAR ANALYSIS
MICE LACKING
P27
TUMORS
GENE
P21(WAF1/CIP1)
DEGRADATION

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/(SICI)1096-9896(199904)187:5<563::AID-PATH292>3.0.CO;2-3

Cite this

@article{6a40fd2d71934d0d87ba07ef88a8d1b7,

title = "Expression of p27/Kip1 is down-regulated in human prostate carcinoma progression",

abstract = "p27(Kip1) is a cyclin-dependent kinase inhibitor whose down-regulation has been observed in several tumour models, including breast, colorectal, and gastric carcinomas. The purpose of this study was to assess p27(Kip1) protein expression in normal and benign prostatic epithelia as well as the possible existence of abnormalities in prostate carcinoma progression. p27(Kip1) expression was immunohistochemically analysed in 51 normal tissue samples, 11 nodular hyperplasias (NH), 22 high-grade prostatic intraepithelial neoplasias (PIN), 56 localized prostate adenocarcinomas, and 19 metastases. Immunoblotting was performed in ten cases. Normal prostate epithelium and NH showed diffuse and intense p27(Kip1) nuclear expression in most cases. A significant p27(Kip1) down-regulation was observed in many carcinomas when compared with benign epithelium, Forty-seven cases (84 per cent) mere low p27(Kip1) expressors (",

keywords = "prostate cancer, prostate intraepithelial neoplasia, anti-oncogene, PIN, p27, Kip1, KINASE INHIBITOR P27(KIP1), CELL-CYCLE, BREAST-CANCER, MOLECULAR ANALYSIS, MICE LACKING, P27, TUMORS, GENE, P21(WAF1/CIP1), DEGRADATION",

author = "PL Fernandez and Y Arce and M. Farre and A Martinez and A Nadal and MJ Rey and N Peiro and E Campo and A Cardesa",

year = "1999",

month = apr,

doi = "10.1002/(SICI)1096-9896(199904)187:5<563::AID-PATH292>3.0.CO;2-3",

language = "English",

volume = "187",

pages = "563--566",

number = "5",

}

TY - JOUR

T1 - Expression of p27/Kip1 is down-regulated in human prostate carcinoma progression

AU - Fernandez, PL

AU - Arce, Y

AU - Farre, M.

AU - Martinez, A

AU - Nadal, A

AU - Rey, MJ

AU - Peiro, N

AU - Campo, E

AU - Cardesa, A

PY - 1999/4

Y1 - 1999/4

N2 - p27(Kip1) is a cyclin-dependent kinase inhibitor whose down-regulation has been observed in several tumour models, including breast, colorectal, and gastric carcinomas. The purpose of this study was to assess p27(Kip1) protein expression in normal and benign prostatic epithelia as well as the possible existence of abnormalities in prostate carcinoma progression. p27(Kip1) expression was immunohistochemically analysed in 51 normal tissue samples, 11 nodular hyperplasias (NH), 22 high-grade prostatic intraepithelial neoplasias (PIN), 56 localized prostate adenocarcinomas, and 19 metastases. Immunoblotting was performed in ten cases. Normal prostate epithelium and NH showed diffuse and intense p27(Kip1) nuclear expression in most cases. A significant p27(Kip1) down-regulation was observed in many carcinomas when compared with benign epithelium, Forty-seven cases (84 per cent) mere low p27(Kip1) expressors (

AB - p27(Kip1) is a cyclin-dependent kinase inhibitor whose down-regulation has been observed in several tumour models, including breast, colorectal, and gastric carcinomas. The purpose of this study was to assess p27(Kip1) protein expression in normal and benign prostatic epithelia as well as the possible existence of abnormalities in prostate carcinoma progression. p27(Kip1) expression was immunohistochemically analysed in 51 normal tissue samples, 11 nodular hyperplasias (NH), 22 high-grade prostatic intraepithelial neoplasias (PIN), 56 localized prostate adenocarcinomas, and 19 metastases. Immunoblotting was performed in ten cases. Normal prostate epithelium and NH showed diffuse and intense p27(Kip1) nuclear expression in most cases. A significant p27(Kip1) down-regulation was observed in many carcinomas when compared with benign epithelium, Forty-seven cases (84 per cent) mere low p27(Kip1) expressors (

KW - prostate cancer

KW - prostate intraepithelial neoplasia

KW - anti-oncogene

KW - PIN

KW - p27

KW - Kip1

KW - KINASE INHIBITOR P27(KIP1)

KW - CELL-CYCLE

KW - BREAST-CANCER

KW - MOLECULAR ANALYSIS

KW - MICE LACKING

KW - P27

KW - TUMORS

KW - GENE

KW - P21(WAF1/CIP1)

KW - DEGRADATION

U2 - 10.1002/(SICI)1096-9896(199904)187:5<563::AID-PATH292>3.0.CO;2-3

DO - 10.1002/(SICI)1096-9896(199904)187:5<563::AID-PATH292>3.0.CO;2-3

M3 - Article

VL - 187

SP - 563

EP - 566

IS - 5

ER -